The purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.

The intensive cream and body lotion of the PediATOPIC® products are two emollients expressly formulated to serve as adjuvants in the management of Atopic Dermatitis. Both products contain Dermosense complex®, a complex that includes 3 products: Bodyfensine peptide® (inductor of dephensine synthesis against microbial aggressions), Unimoist® (the mimetizing complex of the skin's natural hydration factor), and Ramnosoft® (polysaccharide that inhibits the adhesion of pro-inflammatory drugs and bacteria, while limiting the spread of inflammatory reactions in skin cells). They also contain Bisabolol, (plant extract with anti-inflammatory, anti-irritant and antimicrobial properties) and Panthenol (Pro vitamin B5 that accelerates the skin's natural regeneration process).

Inclusion Criteria:

• Children from 1 month to 5 years old
• Patients with atopic dermatitis mild-moderate with an SCORAD=16-40

Exclusion Criteria:

• Other dermatological diseases that could interfere with the study results
• Corticoids use during 3 weeks prior to the study
• Antibiotics use to treat atopic dermatitis during 3 weeks prior to the study
• Use of topical immunomodulators
• Concurrent use of other emollients